Dr. Neha Reshamwala, owner of Frontier Allergy, Asthma & Immunology, with BioBehavioral Research of Austin (BBRA) stopped by ...

Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently ...

Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced promising topline data from the completed Phase 1 clinical trial of its lead mRNA ...

21, 2025 — A new study found that pregnant women are regularly excluded from clinical drug ... and pave the way for research toward better treatments for lesser-studied asthma types, ...

Pregnancy comes with unique health risks and considerations, but pregnant people also continue to experience the same health ...

Peter Thiel-backed Lindus Health has raised $55 million as it sets about "fixing the broken clinical trial industry." ...

Poorly controlled asthma during pregnancy can lead to serious complications, such as low birth weight, preterm delivery, and ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

A Victorian-based company is using AI to help “map” and personalise the best treatment for patients with respiratory ...

A simple, noninvasive nasal swab identified a predominance of T2-low asthma subtypes in racial and ethnic minority pediatric ...

Asthma biologics can be used during pregnancy to reduce the risk of complications associated with the disease. Apostolos ...